Lynx1 Capital Management LP
DORADO, PR · CIK 1910456 · 13F filing filed 2025-08-14
SEC-registered investment adviser since 2023 · limited partnership
- Assets managed$626.7m
- Staff5 · 4 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds2 (1 hedge) · $576.8m gross assets
- Form ADV · 2026-03-31SEC adviser record
- Legal entityLYNX1 CAPITAL MANAGEMENT LP (US)
- Kindhedge funds, private equity, futures
As an employer
- Offices in1 country
- Private fundshedge 1, private equity 1
This report includes the holdings of 1 other manager that shares the investment decisions:
- Lynx1 Capital Advisors LLC – no 13F of its own this quarter
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2025
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| MERUS N V MRUS | $82.5m23.84% | Unchanged |
| GH RESEARCH PLC GHRS | $82.2m23.76% | Added +303.0k |
| STOKE THERAPEUTICS INC STOK | $61.3m17.72% | Added +112.7k |
| PROTAGONIST THERAPEUTICS INC PTGX | $40.5m11.70% | Unchanged |
| CULLINAN THERAPEUTICS INC CGEM | $33.1m9.57% | Added +1.2m |
| ALLOGENE THERAPEUTICS INC ALLO | $12.5m3.61% | Unchanged |
| TSCAN THERAPEUTICS INC TCRX | $11.4m3.29% | Added +2.5m |
| C4 THERAPEUTICS INC CCCC | $10.2m2.93% | Unchanged |
| PRECISION BIOSCIENCES INC DTIL | $4.4m1.26% | Added +270.0k |
| PASSAGE BIO INC COM | $3.7m1.07% | Unchanged |
| UPSTREAM BIO INC UPB | $2.4m0.70% | Unchanged |
| IBIO INC IBIO | $1.2m0.34% | Added +676.3k |
| NEUPHORIA THERAPEUTICS INC NEUP | $325.2k0.09% | Unchanged |
| DESIGN THERAPEUTICS INC DSGN | $222.3k0.06% | Unchanged |
| ASSEMBLY BIOSCIENCES INC ASMB | $187.8k0.05% | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| PASSAGE BIO INC 13D · filed 2026-07-02 | 21.0% |
| GH RESEARCH PLC GHRS · 13G · filed 2026-08-14 | 19.3%≈ $354.0m |
| NEUPHORIA THERAPEUTICS INC NEUP · 13D · filed 2025-12-29 | 16.3%≈ $3.8m |
| TSCAN THERAPEUTICS INC TCRX · 13G · filed 2026-08-14 | 13.1%≈ $3.4m |
| KORRO BIO INC KRRO · 13G · filed 2026-04-02 | 10.7%≈ $20.3m |
| C4 THERAPEUTICS INC CCCC · 13G · filed 2026-08-14 | 10.0%≈ $63.1m |
| CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2025-11-14 | 9.8%≈ $105.0m |
| STOKE THERAPEUTICS INC STOK · 13G · filed 2026-08-14 | 6.5%≈ $132.1m |
| IBIO INC IBIO · 13G · filed 2026-08-14 | 5.4%≈ $4.9m |
| PRECISION BIOSCIENCES INC DTIL · 13G · filed 2026-07-20 | 5.4%≈ $10.9m |
| AGIOS PHARMACEUTICALS INC AGIO · 13G · filed 2026-05-06 | 5.1%≈ $111.8m |
Trades reported as a company insider in Q2 2025
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2025-05-20 | TSCAN THERAPEUTICS INC 10% owner · See footnote | Bought | $1.4m1.2m shares |
| 2025-05-19 | TSCAN THERAPEUTICS INC 10% owner · See footnote | Bought | $1.7m1.4m shares |